Skip to main content
Log in

Pharmakotherapie bei Niereninsuffizienz

Pharmacotherapy and kidney dysfunction

  • Übersichten
  • Published:
Medizinische Klinik - Intensivmedizin und Notfallmedizin Aims and scope Submit manuscript

Zusammenfassung

Maßgeblich für die Arzneimitteldosierung ist die glomeruläre Filtrationsrate (GFR) nicht der Kreatininwert. Bei lebensbedrohlichen Erkrankungen darf man die Startdosis nicht vergessen, die zumeist der Normaldosis entspricht. Die Halbwertszeit gibt Auskunft über die Dauer des Dosierungsintervalls. Für konzentrationsabhängig wirkende Antibiotika, wie Daptomycin, Linezolid oder Colistin, ist ein hoher Spitzenspiegel der Zielspiegel. Für zeitabhängig wirkende Antibiotika ist ein hoher Talspiegel der Zielspiegel. Bei Piperacillin, Meropenem und Vancomycin wird deshalb die Dauerinfusion bevorzugt. Mit kontinuierlichen Nierenersatzverfahren entspricht die Gesamtfiltration oft einer GFR von 30–50 ml/min: Viele Antibiotika kann man dann in voller Normaldosis verabreichen. Nach intermittierender Hämodialyse empfiehlt es sich, eine erneute Startdosis zu geben um danach ausreichende Spiegel zu garantieren.

Abstract

Essential for drug dose adjustment is the glomerular filtration rate (GFR) not the serum creatinine level. In acute disease, a loading dose must be given that usually corresponds to the normal dose. The eliminated half-life is used to estimate the administration interval. For anti-infective drugs with a concentration-dependent effect, the target is the high peak such as for daptomycin, linezolide, and colistin. For anti-infective drugs with a time-dependent effect, the target is the high trough such as for piperacillin, meropenem and vancomycin. Such drugs with a time-dependent action should best be administered by infusion not by bolus dosing. With continuous renal replacement therapy (CRRT), the total filtration rate corresponds to a GFR of 30–50 ml/min and many antibiotics will not need a dose reduction on CRRT. After intermittent hemodialysis, a new loading dose should be given to ascertain sufficiently high concentrations in the interval until the next dose or next dialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Chen S (2013) Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely. J Am Soc Nephrol 24:877–888

    Article  Google Scholar 

  2. Czock D, Spitaletta M, Keller F (2015) Suboptimal antimicrobial drug exposure in patients with renal impairment. Int J Clin Pharm 37:906–916

    Article  CAS  Google Scholar 

  3. Benet LZ, Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121

    Article  CAS  Google Scholar 

  4. Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ (2017) Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. J Antimicrob Chemother 72:900–905

    CAS  PubMed  Google Scholar 

  5. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D et al (2016) Efficacy and Safety of Ceftazidime-Avibactam (CAZ) Plus Metronidazole Versus Meropenem (MER) in the Treatment of Complicated Intraabdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 62:1380–1389

    Article  CAS  Google Scholar 

  6. Luque Y, Louis K, Jouanneau C, Placier S, Esteve E, Bazin D, Rondeau E, Letavernier E, Wolfromm A, Gosset C, Boueilh A, Burbach M, Frère P, Verpont MC, Vandermeersch S, Langui D, Daudon M, Frochot V, Mesnard L (2017) Vancomycin-associated cast nephropathy. J Am Soc Nephrol 28:1723–1728

    Article  Google Scholar 

  7. Brinkmann A, Röhr AC, Köberer A, Fuchs T, Preisenberger J, Krüger WA, Frey OR (2018) Therapeutic drug monitoring and individual dosing of antibiotics during sepsis: modern or just „trendy“? Med Klin Intensivmed Notfmed 113:82–93

    Article  CAS  Google Scholar 

  8. Martinez MN, Papich MG, Drusano GL (2012) Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 56:2795–2805

    Article  CAS  Google Scholar 

  9. Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME (2018) Prolonged versus short-term intravenous infusion of antipseudomonal β‑lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 18:108–120

    Article  CAS  Google Scholar 

  10. Álvarez O, Plaza-Plaza JC, Ramirez M, Peralta A, Amador CA, Amador R (2017) Pharmacokinetic assessment of vancomycin loading dose in critically ill patients. Antimicrob Agents Chemother:e00280-17. https://doi.org/10.1128/AAC.00280-17

    Article  PubMed  PubMed Central  Google Scholar 

  11. Czock D, Schwenger V, Kindgen-Milles D, Joannidis M, John S, Schmitz M et al (2018) Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine: Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI. Med Klin Intensivmed Notfmed 113(5):384–392

    Article  CAS  Google Scholar 

  12. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB, LEADER Steering Committee and Investigators (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848

    Article  CAS  Google Scholar 

  13. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, Meininger G, Bakris G (2014) Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 40:64–74

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F. Keller.

Ethics declarations

Interessenkonflikt

F. Keller gibt folgende Interessenskonflikte an: Referentenhonorare von Novartis, TEWA, Astellas, Roche, Alexion, Medice, Hexal, Bayer, Pfizer, MSD, Aspen, Akademie Niere und Beschäftigungsverhältnis mit KfH und Universitätsklinikum Ulm.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Buerke, Siegen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keller, F. Pharmakotherapie bei Niereninsuffizienz. Med Klin Intensivmed Notfmed 114, 444–451 (2019). https://doi.org/10.1007/s00063-018-0455-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-018-0455-5

Schlüsselwörter

Keywords

Navigation